LOBEF Stock Chart & Stats
$0.04
>-$0.01(-17.06%)
At close: 4:00 PM EST
$0.04
>-$0.01(-17.06%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume171.00
Average Volume (3M)103.94K
Market Cap
$18.17M
Enterprise Value$13.06
Total Cash (Recent Filing)$4.96M
Total Debt (Recent Filing)$316.49K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume62,263
30 Day Avg. Volume103,939
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused IP-driven R&DThe company’s explicit focus on psychedelic-assisted therapies and pursuit of intellectual property around novel delivery methods creates a durable strategic edge. Proprietary formulations and delivery IP can form long-term barriers, enable licensing or partnerships, and increase eventual commercial leverage if clinical progress continues.
Low Reported LeverageModest reported debt reduces near-term solvency pressure and gives the company more optionality when raising capital for development programs. A low debt burden is a durable balance-sheet strength that lowers fixed financing costs and preserves flexibility across multi-quarter R&D timelines.
Positive Unit Economics Observed HistoricallyHistorical intervals with meaningful gross profit imply the underlying product or distribution model can achieve positive unit economics. That suggests the core business can support margins once scale or commercialization is achieved, a structurally important indicator for sustainable profitability potential.
Bears Say
No Recent Revenue And Sizable LossesThe absence of current revenue alongside repeated operating and net losses is a fundamental constraint: the company is not yet commercialized and must support operations through external funding. Over a multi-quarter horizon, continued losses increase execution risk and lengthen the path to self-sustaining operations.
Persistent Negative Cash FlowSustained negative operating and free cash flow indicate ongoing cash burn, forcing reliance on equity or debt raises to fund R&D and operations. This structural cash gap can dilute shareholders, constrain long-term program funding, and limit the firm’s ability to execute multi-stage clinical or commercialization plans without material external support.
Unstable Equity And Capital BasePeriods of negative equity and materially swinging asset levels point to a volatile capital base that can hinder access to favorable financing and strategic partnerships. Structurally, this raises counterparty and lender concerns and can increase the cost or reduce the availability of capital needed to sustain long development cycles.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $18.17M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.095%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―